Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.
about
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicinePlasma membrane transporters in modern liver pharmacologyThe role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapyAdvances in non-surgical management of primary liver cancer.Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells.Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.Molecular mechanism of chemoresistance by astrocyte elevated gene-1.ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.Dehydroabietic acid derivative QC2 induces oncosis in hepatocellular carcinoma cells.Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.Polymorphisms in the ABC drug transporter gene MDR1.Cancer chemoresistance: the relationship between p53 and multidrug transporters.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis.Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.Mechanisms of doxorubicin resistance in hepatocellular carcinomaMultifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful?Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells.Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial InfusionFolate-targeted paclitaxel-conjugated polymeric micelles inhibits pulmonary metastatic hepatoma in experimental murine H22 metastasis modelsSorafenib in hepatocellular carcinoma.Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma.ATP-binding cassette transporters in liver.Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.Effect of Liver Disease on Hepatic Transporter Expression and Function.Immunohistochemical expression of MDR1-Pgp 170 in canine cutaneous and oral melanomas: pattern of expression and association with tumour location and phenotype.Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway.Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.The Toxic Effects of Polychemotherapy onto the Liver Are Accelerated by the Upregulated MDR of Lymphosarcoma.Evolution of systemic therapy of advanced hepatocellular carcinoma.Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.Molecular characteristics of hepatocellular carcinomas from different age groups.Induction of apoptosis by an oleanolic acid derivative in SMMC-7721 human hepatocellular carcinoma cells is associated with mitochondrial dysfunction.Hepatobiliary transporter expression in human hepatocellular carcinoma.
P2860
Q26776095-1CF6692C-3F0F-4B46-B0E9-FDC373B58188Q26829263-7AE46E68-1EF9-4533-AED0-7291B7AF4736Q26830005-2FCBA254-013C-4B30-BEAA-FDA2BF936B6CQ30423781-06204702-2F8C-4479-AAF8-7AA2A9FC505AQ33358104-6CDD9038-2309-430B-89EC-D8A2D8A83BA3Q33414726-1847821F-B5F4-43A8-AA50-AE0ADB553C21Q33567539-BC38713B-BADF-4E7F-B075-3EF0D2BFDCFEQ33788566-EAAA9215-6F41-4574-BB56-91C5E443CCF6Q33793969-2940D9AA-1BFC-4AD8-8BE4-FE2113CE860AQ33938893-AF162C2E-1F55-43B5-91AE-96DB4CC3CDBCQ33943367-2C5921E9-A561-4813-A9F7-FE90A4DA7863Q34124356-09771DDD-F977-4D4B-B1AF-41280A9686CAQ34576932-CC710886-08A0-44F1-8F33-DC687D38C2CFQ34580489-31BA75BE-7443-4ACB-B883-6D9B5412DC5BQ34632966-7DC149F9-D033-4B2B-94CB-CC37E381C408Q35791300-9185A1E0-83A7-40D5-861C-CEEB1A535A8BQ36156854-8724B27C-0923-4564-AD2A-15CB56B05601Q36687760-8D32B60C-E093-4C48-82DB-3FF8140D50CEQ36804306-A06B1AA0-4BA1-4C3E-8B58-BB05F14AC559Q37092712-0E90F5B0-3257-404F-9FAA-D4DBB6B71BFBQ37666690-483F5B96-1733-4D7B-8ACA-75A270BDF055Q37729748-9DA694D2-3D6E-49D6-9547-3C665EADF47AQ37790248-8ADCEBF8-8D8F-40E9-97E8-2131872835B5Q37821305-D18A16F5-9697-4D4E-B32B-1E83C437111BQ38150795-C30CFC0B-C145-4D2A-821F-18BE8295D725Q38213800-2B306EEA-1458-4F1C-8F3F-0FD49C6859A1Q38808182-D819E93B-D72E-45A4-B0BD-1B19486503C7Q39251469-A1ED9297-2C73-4619-AED3-2B83CCF97FB2Q39545301-FC184FD7-03BB-42F1-9D85-A1382BB1D171Q39909012-0B5E62B5-7426-4E01-B4FB-FDC9DE6D46BFQ41813332-27714B47-5328-44B5-85B8-DC88C5DA345CQ42617015-FD04ECDF-7F66-400A-9029-FFA8E0A245FBQ43215356-B6A7CB4D-0B58-4E10-91DB-FFB955D08A50Q46905311-C7D44E03-A1DE-4563-8082-458CC2ABD558Q47143106-CECB2E80-89B3-4EB2-BC1F-8265E7D2FCF1Q50295737-11246CB4-ACB1-46ED-945C-1202D25EE54DQ54674953-AB6A3961-06EC-4ED4-9640-27368DF62AF2
P2860
Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@ast
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@en
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@nl
type
label
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@ast
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@en
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@nl
prefLabel
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@ast
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@en
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@nl
P2093
P1476
Expression of P-glycoprotein i ...... nant of chemotherapy response.
@en
P2093
P304
P356
10.1309/AC1M-4TY4-U0TN-EN7T
P407
P577
2000-03-01T00:00:00Z